Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$39.62 - $69.97 $11.6 Million - $20.5 Million
-292,735 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $300,906 - $427,401
-5,180 Reduced 1.74%
292,735 $19.4 Million
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $110,396 - $160,659
1,891 Added 0.64%
297,915 $18.6 Million
Q1 2021

May 07, 2021

SELL
$61.35 - $90.47 $163,375 - $240,921
-2,663 Reduced 0.89%
296,024 $19.6 Million
Q4 2020

Feb 16, 2021

SELL
$43.82 - $85.37 $2.89 Million - $5.63 Million
-65,949 Reduced 18.09%
298,687 $23.1 Million
Q3 2020

Nov 13, 2020

BUY
$33.21 - $51.27 $9.75 Million - $15 Million
293,437 Added 412.14%
364,636 $15.7 Million
Q2 2020

Aug 14, 2020

BUY
$26.12 - $43.27 $1.86 Million - $3.08 Million
71,199 New
71,199 $3.08 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track L1 Capital Pty LTD Portfolio

Follow L1 Capital Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of L1 Capital Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on L1 Capital Pty LTD with notifications on news.